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1. Introduction 
Since the first draft of the human genome we observed a boost in biomedical research. As 
consequence, nowadays, it is possible to know a person’s predisposition to a genetic disease 
or even how its organism will metabolize a given drug. Although, there is some delay in 
translating this knowledge to the development and implementation of personalized 
medicine, there are currently available some successful pharmacogenetic based treatment 
decisions. One of such example is abacavir, a nucleoside analog reverse transcriptase 
inhibitor used in treatment of HIV-1 infection. Abacavir hypersensitivity is strongly 
associated with HLA-B*57:01 allele. Genetic testing before abacavir’s prescription is now 
recommended in clinical guidelines and is practiced in most western countries (Chaponda & 
Pirmohamed 2011). In a near future, personalized medicine will, most certainly, bring 
considerable health gains to society. 
The new approaches to analyze the human genome, – genome-wide association studies 
(GWAS; Orange et al., 2011), deep resequencing (1000 Genomes Project Consortium, 2010) 
and gene expression variability (Li et al., 2010) –, are producing massive data, which are 
already historic marks in the understanding of the genetic makeup of traits. A good example 
is the 9p21 genomic region association with coronary artery disease (McPherson et al., 2007; 
Helgadottir et al., 2007). However, only a small fraction of the heritable variation of complex 
diseases has been identified. One possible explanation may be that many rare variants, 
which are not included in the common genotyping platforms, may contribute substantially 
to the genetic variation of complex diseases. Therefore, researchers are becoming aware that 
common disease – common variant and common disease – rare variant models (Gorlov et 
al., 2011; Carvajal-Carmona, 2010; Zhu et al., 2011) will largely contribute to understand the 
genetic architecture of the populations with a diverse ancestry, such as the Azoreans. Hence, 
regional and local studies are good approaches to comprehend the genetic specificities of 
each population.  
1.1 Mainland Portugal and Azores populations: historic and demographic data 
Portugal, with a population of 10,637,713 inhabitants, is the most western country of the 
European continent and is bordered by the Atlantic Ocean to the west and south and by 
Spain to the north and east. The present Portuguese genetic landscape is the outcome of an 
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old and slow process of gene flow, admixture with many different populations and local 
differentiation. These include the expansion from isolated population nuclei in refuges 
following the Last Glacial Maximum, the movement of peoples related to the introduction of 
agriculture, and subsequent Roman and Germanic invaders, which may have influenced the 
distribution of genetic diversity in the territory (Amaral & Amaral, 1997). Roman settlers 
strongly influenced Portuguese culture, particularly the Portuguese language, which is 
derived from Latin. During the 8th century Muslim Moors occupied most of the Iberian 
Peninsula, contributing also to admixture events observed by the presence of north African 
paternal lineages in the Portuguese genetic background (Adams et al., 2008; Pereira et al., 
2000a). With the establishment of the country in the year 1139, after several wars, Portugal is 
the oldest European nation-state. In the 15th and 16th centuries, as the result of maritime 
expeditions, the country established a global empire that included possessions in Africa, 
Asia, Oceania and South America, becoming the world's major economic, political and 
military power. Portugal's empire was the first and most long-lived global empire in the 
world, spanning almost six centuries (Russel-Wood, 1998; Jenkins & Sofos, 1996). During the 
Portuguese age of discovery, two archipelagos – Madeira and Azores (Figure 1) –, which are  
 
 
Fig. 1. Portugal’s regions map. 
currently part of the country’s territory, were discovered. The Azores is composed of nine 
volcanic islands unevenly distributed by three geographic groups: the Eastern group with 
two islands – São Miguel and Santa Maria –, the Central includes five islands – Terceira, 
Pico, Faial, São Jorge and Graciosa –, and the Western group with Flores and Corvo. This 
archipelago has a total area of 2332.74 km2, unevenly distributed by the nine islands, 
varying from São Miguel, the largest, with 746.82 km2 to Corvo, the smallest, with 17.13 km2. 
The present-day population is composed of 241,763 inhabitants (National Institute of 
Statistics – Portugal, 2001 Census), derived from about 27 generations. The majority of the 
population lives on São Miguel (54.4%). The remainder is unevenly dispersed throughout 
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the other eight islands; for example, Corvo has only 425 individuals. From the total Azorean 
population, 41.4% are living in the Central group, where Terceira is the most populated of 
this group (24.9%; 55,833 inhabitants). The first settlers arrived in the mid 15th century and 
were mainly Portuguese, but the peopling was a slow and difficult process (Mendonça, 
1996; Guill, 1993). Someone wrote “…The Azorean settlement was done with people from 
the interior of mainland Portugal, those who could not swim nor build boats, making 
impossible the abandonment of the islands…”. Historical data report that the Portuguese 
crown was compelled to give out land and privileges in order to attract people to the islands 
(Guill, 1993). The first islands to be settled were Santa Maria and São Miguel in 1439 and the 
last were Flores and Corvo in the beginning of the 16th century. Some early settlers were of 
foreign origin, including Flemish, Jews, Moorish prisoners and black slaves from Guinea, 
Cape Verde and São Tomé. In the following centuries, contributions from Spanish, French, 
Italians, Germans and Scottish also occurred. 
2. DNA banking of the healthy Azorean population 
Biobanks have become an absolute requirement for biomedical research (Simon et al., 2007; 
Deplanque et al., 2009) and are defined as collections of samples of human bodily 
substances that are or can be associated with personal and clinical data. Depending on the 
purpose of a given biobank, both genetic and health information may be linked with the 
samples. The location of the Azorean population in the middle of the Atlantic, its 
geography, socio-cultural characteristics and, finally, the same environmental conditions, 
make a priori this population a good model to perform population genetic studies. Bering 
this in mind, the Molecular Genetics and Pathology Unit (UGPM, located at the main 
Azorean Hospital, Hospital of Divino Espírito Santo of Ponta Delgada, EPE - HDESPD) 
researchers adopted a strategy that began with the establishment of a DNA bank of the 
Azorean healthy population. Currently, it comprises a collection of 1558 representative 
genetic samples obtained from healthy non-family-related adult volunteers. The blood 
collection counted with the collaboration of the Department of Haematology of HDESPD for 
São Miguel samples, and municipalities Health Centres (Centro de Saúde de Vila do Porto, 
Centro de Saúde de Angra do Heroísmo, Centro de Saúde da Praia da Vitória, Centro de 
Saúde da Calheta, Centro de Saúde de Velas, Centro de Saúde de Santa Cruz da Graciosa, 
Centro de Saúde da Horta, Centro de Saúde das Lajes, Centro de Saúde da Madalena, 
Centro de Saúde de São Roque, Centro de Saúde de Santa Cruz das Flores) of volunteers 
resident in the other eight islands. As part of the research project entitled “Study of the 
genetic diversity in the Azorean population”, the biobank was approved by the local Ethics 
Committee, and follows the international ethical guidelines, which include informed 
consent, confidentiality, anonymity of personal data and abandonment option in case of 
expressed will. To each volunteer was hand-out a leaflet (Figure 2) explaining thoroughly: 
(1) the purpose of the study; (2) the involvement in the blood donation process and of 
personal information sharing; (3) the risks and benefits of participation; and (4) the privacy 
protection measures.  
A code number was assigned to each blood sample, identifying it during the whole project’s 
protocol. Only authorized staff at the previously mentioned blood collection facilities had 
access to the participant’s name. After individual’s acceptance, written informed consent 
was signed and, with the help of the team involved, an anonymous blood sample record 
was filled, providing information regarding the participant’s age, sex, birthplace and 
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parental birthplace. As far as São Miguel is concerned, the sample consisted of 7.5mL of 
blood, while in the other islands only 2.7mL were collected. In order to assure individual 
ancestral origin, the blood collection was preferably taken from individuals whose parents 
were born in the same island. A thorough analysis of the parental birthplace revealed a 
distribution of individuals by four different groups (Table 1).  
 
 
Fig. 2. Leaflet containing information for participation in the Azores DNA bank. 
 
Parents origin 
Samples 
No. % 
Both parents were born in the same island 1373 88,13 
Both parents were born in different Azores islands 70  4,49 
Only one parent was born in the Azores islands 59 3,79 
No parents born in the Azores islands 56 3,56 
Individuals that inhabit the Azores islands 1558 100,00 
Table 1. Parental birthplace analysis of the individuals that compose the Azorean DNA 
bank. 
A total of 1443 individuals (92.6%) presented Azorean parents. Age and sex distribution 
show an average age of 42 years old, ranging from 18 to 88 years, and the majority of 
individuals are men (71%, Figure 3). Considering the individuals who both parents were 
born in the same island (N=1373), the population representativeness varies from 0.2% 
(Terceira) to 7% (Corvo). The largest sample representation is observed in São Miguel with 
64% (Figure 3). The relation between the number of inhabitants and samples in each island 
STUDY OF THE GENETIC DIVERSITY IN THE AZOREAN POPULATION
This leaflet is intended to inform you about the objectives and goal of the study entitled “Study of the genetic diversity in the Azorean 
population”. We aim that after this inf ormation you decide free and clearly whether or not you want to participate. In the affirmative case your 
participation consists in donating 2.7 mL of blood to the Hospital of Divino Espírito Santo of Ponta Delgada, EPE (HDES) collected in the Health
Centre of your residence . Your sample will be used to extract genetic material which will be stored at the Molecular Genetics and Pathology 
Unit (UGPM)of the HDES.
Why is this study being done?
The purpose of this study is to identify 
and quantify the genetic variation that is 
present in the population of the different 
Azorean islands , analysing t he diversity 
present in the genetic material (DNA).
Is my participation important? 
Yes, your particip ation is very important 
because this study is only possible if a 
large number of Azorean blood samples 
are analyzed. You will contribute to a 
better understanding of the origin , nature
and distribution of genetic disorders in 
the Azorean. 
What should I do to participate?
To participate you have to donate 2,7 ml 
of blo od for DNA extraction . With the 
help of a specialized team in the Heath 
Centre, you will fill an anonymous record
of the blood sample , providing
information concerning your age, sex, 
birth place and your parent’s birth place.
How will my personal informa tion be kept 
private? 
After your blood sample is collected a code 
number will be assigned which will identify 
sample during this project protocol. Only 
the Heath Centre will have access to your 
name, thus guaranteeing the anonymous 
nature of the genetic material and 
corresponding personal information.
Are there any risks associated with this 
study?
No, there are no risks associated with this
study.
Are there any financial benefits in taking 
part in this study?
No, there is no financial gratification in 
taking part in this study.
Do I have to pay to participate in the 
project?
No, your participation is volunteer and free
of any charge.
What will happen to my sample after the 
study is over?
After this study is over, your sample will 
be stored at MGPU and used in future 
studies, following all national and 
international ethic regulations . 
What are my rights as a participant?
You are free to choose if you want to 
participate or not; no restrictions will be 
imposed on you.
Who do I call if I have questions or 
problems?
If you have any concerns or questions 
relating this project , please contact the 
MGPU.
Can I leave this project even after I have 
signed the informed consent? 
Yes, you are free to leave the project at 
any time and we will destroy your samp le 
and personal data. All you need to do is 
inform your Heath Centre of your 
intention.
* This study was approved by the Hospital of Divino Espirito Santo of Ponta Delgada, EPE, Ethics Committee.
*
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indicates a very high correlation coefficient (r=0.92; p<0.01), demonstrating the sample 
representativeness of the population distribution by all nine Azores islands. 
Overall, Azoreans were willing to participate and understood its importance for long-term 
health gains. Until now, no requests to remove samples have been made. This biobank 
constitutes a very significant resource for biomedical research in Azoreans, some of them 
described below. 
 
 
Fig. 3. DNA bank samples distribution by sex, age and general Azores population 
representativeness. Calculations were based only in the individuals whose parents were 
born in the same Azorean island (N=1443). 
3. Population studies: knowing the past to predict the future 
The plethora of genomic research, produced since the first draft of the human genome 
(Venter et al., 2001; International Human Genome Sequencing Consortium, 2001), led to the 
acknowledgment that disease related rare variants with small effects are very difficult to 
identify (Figure 4) and that common variants implicated in complex diseases are frequently 
determined by GWAS. Additionally, the Human Genome Project 
(http://www.genome.gov/ 10001772) also contributed to the understanding of the 
structure and organization of the genome. Variability is observed through single nucleotide 
polymorphisms (SNPs), variable number of tandem repeats (VNTRs; e.g. mini and 
microsatellites), presence or absence of transposable elements (e.g. Alu elements) and 
structural alterations, which include insertions, deletions, duplications, inversions, 
translocations and copy number variants (CNVs).  
The global analysis of population neutral variation is an essential part in the comprehension 
of the disease related variation, since it has also been subject to evolutionary forces, such as, 
17
122
199 205 202 188 180
138
71
55
26 25 15
0
50
100
150
200
250
< 
20
y
21
-
25
y
26
-30
y
31
-35
y
36
-
40
y
41
-45
y
46
-
50
y
51
-55
y
56
-
60
y
61
-65
y
66
-70
y
71
-
75
y
> 
76
y
No
. 
o
f i
n
di
v
id
ua
ls
Man
Woman
30%
70%
N = 1025
(71%)
N = 418 
(29%)
2% 3% 4%
4%
4%
5%
6%
8%64%
Corvo
Graciosa
Santa Maria
Faial
São Jorge
Pico
Flores
Terceira
São Miguel
Population representativeness
Sex distribution Age groups
Azores demographic data
Islands Area (km2) Inhabitants 
São Miguel 746.82 131,609 
Santa Maria 97.10 5578 
Terceira 402.20 55,833 
Pico 447.00 14,806 
Faial 172.43 15,063 
São Jorge 237.59 9674 
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genetic drift, mutation, selection and migration. Altogether, the perception of our “roots” 
and genetic signature has several implications in society’s own knowledge, in the design of 
future genetic studies, as well as, in the healthcare system.  
 
 
Fig. 4. The frequency spectrum of human disease risk alleles includes alleles at all 
frequencies from rare to common, with effect sizes from high to low (from Manolio et al., 
2009).  
3.1 Diversity, ancestry and linkage disequilibrium 
The comprehension of how genetic diversity is structured in the human being is not only of 
anthropological importance, but also of medical relevance with significant implications for 
human evolution, forensics, genetic diseases and pharmacogenetics (1000 Genomes Project 
Consortium, 2010; The International HapMap Consortium, 2010; Heard et al., 2010). As 
more geographic populations are studied with high density genotype arrays it is also 
becoming apparent that allele frequencies for the relevant disease markers can vary widely. 
For instance, what is true for Europeans may not be for Africans, such is example the Type 2 
Diabetes protective allele with increased frequency in non-Africans compared to Africans 
(Silander et al., 2009; Kral et al., 2011). These emerging data must be incorporated into a 
strategy that positions genomic medicine for a clinical role.  
To grasp the genetic origins of mainland Portugal and Azorean populations studies on Y-
chromosome lineages (Pacheco et al., 2005; Montiel et al., 2005; Beleza et al., 2006; Gonçalves 
et al., 2005; Fernando et al., 2005), mitochondrial DNA (Pereira et al., 2000b; Santos et al., 
2003; Santos et al., 2005; Santos et al., 2008; Santos et al., 2010) and autosomal Alu insertion 
polymorphisms (Branco et al., 2006) were performed. The nonrecombining portion of the Y-
chromosome retains a record of the mutational events that occurred along male lineages 
throughout evolution (Karafet et al., 2008). Presently, new binary polymorphisms reshaped 
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and increased resolution of the Y-haplogroup tree; however, for comparison purposes old 
nomenclature was maintained. According to Pacheco et al. (2005), the Azorean population 
presented nine different haplogroups, most of which are frequent in Europe (Figure 5). 
Hapogroup J* is the second most frequent in Azores (13.4%), but it is modestly represented 
in mainland Portugal (6.8%). The other non European haplogroups – N3 and E3a –, which 
are prevalent in Asia and subSahara, respectively, have been found in Azores (0.6% and 
1.2%, respectively) but not in mainland Portugal (Neto et al., 2007). The absence of 
haplogroup E3a in western Iberia suggests that, despite the massive introductions of African 
slaves in historical times, there was little admixture between the African males and western 
Iberian populations (Pereira et al., 2000a). In general, four major haplogroups –
P*(xR1b8,R1a,Q3), J*, BR*(xB2b,CE,F1,H,JK) and E*(xE3) – account for the majority of the 
male lineages in the Azores and mainland Portugal. 
 
 
 
Fig. 5. Phylogenetic tree of the Y-chromosome haplogroups and their percent frequencies in 
the Azores and mainland Portugal. Numbers of % individuals with HG for mainland 
Portugal represent average values based on literature reports by Beleza et al. (2006) and 
Gonçalves et al. (2005).  
All studies (Pacheco et al., 2005; Montiel et al., 2005; Beleza et al., 2006; Fernando et al., 2005) 
report that the main contributors to the genetic origin of the Azores are, as expected, the 
mainland Portuguese. Moreover, an important contribution of Middle eastern (HG J*) and 
north African (HG E*(xE3)) populations is observed in both populations. This observation is 
corroborated by mitochondrial DNA HVRI (hypervariable region I) analysis, where the 
majority of mtDNA lineages originated from the Iberian peninsula, mainly from mainland 
Portugal. The presence of Jews in the Azorean Central group is also supported by the 
mtDNA data (Santos et al., 2003).  
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Without any doubt, Y-chromosome and mtDNA studies are crucial to address the origin of 
the population; however, a population loses mtDNA when a woman has only sons and Y-
chromosome DNA when a man has only daughters. As a result, these genetic markers may 
give less correct information on broad ancestry of most genes in a population. A full picture 
of the histories of populations requires studies of markers in the recombining parts of the 
nuclear DNA, namely the autosomes. Albeith several types of markers can be used to 
achieve this purpose, Alu insertion polymorphisms present some interesting advantages. 
These markers arose within the human population as a unique event in evolutionary 
history, making Alu repeats identical by descent from a common ancestor (Batzer & 
Deininger, 2002). Moreover, the ancestral state, which is absence of the Alu insertion, is 
always known. The allele frequencies for each Alu polymorphism in Azoreans and 
mainland Portugal (Table 2) are very similar to those obtained in other European 
populations.  
 
Population N 
Autosomal Alu insertion polymorphisms 
TPA-25 ACE APO PV92 D1 B65 
Azores 65       
 Frequency  0.592 0.385 0.946 0.208 0.254 0.585 
 Heterozygosity  0.424 0.485 0.106 0.257 0.348 0.409 
 HW (p value)  0.323 1.000 1.000 0.033 0.524 0.211 
 Locus diversity   0.493 0.481 0.117 0.343 0.392 0.493 
 Av. gene 
diversity 
 0.383 +/- 0.233 
 FIS  0.117 
        
Portugal 30       
 Frequency  0.600 0.367 0.917 0.283 0.233 0.500 
 Heterozygosity  0.517 0.483 0.034 0.345 0.275 0.483 
 HW (p value)  0.665 1.000 0.073 1.000 0.453 1.000 
 Locus diversity  0.496 0.480 0.128 0.404 0.370 0.517 
 Av. gene 
diversity 
 0.392 +/- 0.240 
 FIS  0.094 
Table 2. Alu insertion frequencies, heterozygosity and gene diversity for Azores and 
mainland Portugal. FIS represents inbreeding coefficient (from Branco et al., 2006). 
The evolution of populations is dependent on several mechanisms, such as migration, 
genetic drift, selection and mutation, all affecting the patterns of diversity of neutral and 
disease variants. Consequently, the measure of diversity of neutral markers allows the 
inference of how these processes are shaping the overall signature of a population and has 
further implications in the general diseases apportionment. Genetic diversity values, based 
on autosomal STR markers, for Azores (0.788; Branco et al., 2008a; Santos et al., 2009) and 
mainland Portugal (0.782; Perez-Lezaun et al., 2000) indicate that both populations are very 
diverse. Studies of HLA markers in mainland (Spinola et al., 2005a; 3 loci) and in Azores 
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(Spinola et al., 2005b; 6 loci) demonstrate values of average diversity of 0.92. The results 
obtained for Azores (Pacheco et al., 2010), based in 7 loci, presented a smaller value (0.83). 
HLA haplotype analysis showed that A*01-B*08-DRB1*03 haplotype, known to be of Indo-
European Celtic origin, is present in Centre and North Portugal regions at relatively low 
frequencies of 3% and 2.2%, respectively. However, this haplotype is the most frequent in 
São Miguel Island (8%). According to Spínola et al. (2005b), it’s presence results from a 
colonizing event from people originating from the Centre of Portugal.  
The patterns of genetic diversity of a population have a direct influence in the linkage 
disequilibrium (LD) extent, which has been found to improve the knowledge of human 
evolution and origin, and to identify genes causing disease. Table 3 describes the number of 
haplotypes, gene diversity and standardized multiallelic disequilibrium coefficient (D’), 
based on X-linked markers for Azores and mainland Portugal populations (Branco et al., 
2008b; Branco et al., 2009).  
 
Populations HN GD D' 
Azores   
 Western group 93 0.718 0.328 
 Central group 150 0.690 0.189 
 Eastern group 207 0.686 0.176 
 Total 450 0.695 0.142 
mainland Portugal 97 0.683 0.226 
Table 3. Haplotype number (HN), gene diversity (GD) and standardized multiallelic 
disequilibrium coefficient (D’) for Azorean and mainland Portugal populations (from 
Branco et al., 2008b). 
The Azorean Western group shows a higher genetic diversity (0.718) when compared with 
the other two groups. Overall, Azoreans and mainland Portuguese do not show extensive 
LD, as direct consequence of the large genetic diversity of these populations. These data 
were also corroborated by Silva et al. (2010), based on pairwise linkage of 10 X-chromosome 
STRs, and Service et al. (2006), who compared levels of LD between several European 
populations. Finally, both mainland Portuguese and Azoreans constitute admixed and 
outbred populations.  
4. Studies of rare and common genetic diseases 
Population genetic architecture can also be revealed by distribution patterns of mutations 
causing Mendelian disorders. Bering this in mind, the UGPM developed three main 
research areas, based on the Azorean healthy population. The first encompassed the analysis 
of mutations causing Gilbert’s syndrome (GS) and hereditary haemochromatosis (HH), the 
second constituted the evaluation of some genetic variants predisposing to complex 
diseases, namely, congenital heart diseases (CHD) and thrombosis, and, finally, the third 
included the characterization of variants involved on drug metabolism, particularly, 
irinotecan and warfarin. The results from these research projects are presented and 
discussed in this section. 
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4.1 Gilbert’s syndrome 
Gilbert syndrome is a mild hereditary unconjugated hyperbilirubinemia without liver 
dysfunction or hemolytic anemia (Matsui et al., 2010; Zhang et al., 2007). No treatment or 
long-term medical attention is necessary and it is usually one of the differential diagnoses of 
liver or hemolytic disease. The primary cause of this syndrome is the accumulation of 
bilirubin – hyperbilirubinemia –, due to decreased hepatic activity levels of glucoronosyl 
transferase, an enzyme responsible for glucoronidation reaction (Figure 6; Matsui et al., 
2010).  
 
 
Fig. 6. Bilirubin uptake and processing in the liver cell. The heme initially breaks apart into 
biliverdin, which is rapidly reduced to bilirubin (1). Bound to albumin, bilirubin is 
transported from sites of production to hepatic sinusoids (2). At the sinusoidal surface of 
hepatocytes, bilirubin dissociates from albumin and enters hepatocytes by facilitated 
diffusion (3). Binding to cytosolic glutathione-S-transferases (GSTs) increases net uptake of 
bilirubin by inhibiting its efflux (4). Bilirubin is converted to mono- and diglucuronide by 
the action of UGT1A1, which catalyses the transfer of the glucuronic acid moiety from UDP-
glucuronic acid (UDPGA) to bilirubin (5). Bilirubin glucuronides are actively transported 
into bile against a concentration gradient by the ATP-utilizing pump MRP2 (6; Figure from 
http://www.natap.org/2011/EASL/EASL_83.htm).  
Bilirubin has been shown to inhibit DNA synthesis, uncouple oxidative phosphorylation, 
and inhibit ATPase activity in brain mitochondria (Strassburg, 2010). It also inhibits a 
variety of different classes of enzymes including dehydrogenases, electron transport 
proteins, hydrolases, enzymes of RNA synthesis, protein synthesis and carbohydrate 
metabolism. All toxic effects of bilirubin are reversed by binding to albumin. In fact, 
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albumin plays a vital role in the distribution of bilirubin in the body by keeping the 
compound in solution and transporting it from sites of production (primarily bone marrow 
and spleen) to the liver (Strassburg, 2010). 
GS is associated with a dinucleotide polymorphism in the TATA box promoter of the UDP 
glucuronosyltransferase 1 (UGT1A1) gene, more precisely the UGT1A1*28 allele (Costa, 
2006). In São Miguel Island a group of 67 suspected GS patients and 469 unrelated healthy 
blood donors were studied (Pacheco et al., 2006; Table 4). The results demonstrated that 
65.9% of patients (45 out of 67) and 9.2% controls (43 out of 469) were homozygous for allele 
*28/*28. The genotype frequency in the control group showed a similar value to the 
reported to mainland Portugal (9.9%; Gonçalves et al., 2001). Additionally, Oliveira et al. 
(2007) reported, in a group of healthy individuals, an UGT1A1*28 allele frequency of 28.0%, 
a value very similar to the obtained in the Azorean control group (29.0%; Pacheco et al., 
2009). 
 
UGT1A1 
 Genotype frequency 
Suspected GS patients 
(N=67) 
 Control group 
(N=469) 
Alleles Genotypes  N %  N % 
*1 A[TA]6TAA *1*1  4 6.0  237 50.5 
*28 A[TA]7TAA *1*28  18 29.9  186 39.7 
*36 A[TA]5TAA *1*36  - -  2 0.4 
*37 A[TA]8TAA *1*37  - -  1 0.2 
  *28*28  45 65.9  43 9.2 
Table 4. Genotype frequencies of UGT1A1 variants in suspected GS patients and control 
group in São Miguel islanders (adapted from Pacheco et al., 2006). 
A molecular study based in a cohort of 120 Portuguese patients with the clinical diagnosis of 
Gilbert syndrome demonstrated that 110 individuals were homozygous for the UGT1A1*28 
allele (*28/*28), and one patient was a compound heterozygote for two different insertions 
*28/*37. The remaining 9 patients were heterozygous, *1/*28 (Costa et al., 2006). The 
analysis of the control group allowed the identification of alleles characteristic of African 
populations, *36 (0.2%) and *37 (0.1%), which corroborates previous data on the Azorean 
and mainland Portuguese genetic background. 
4.2 Hereditary hemachromatosis 
Hereditary haemochromatosis (HH) is an inherited disorder characterized by accumulation 
of iron. The phenotypic condition was uncommon and typically diagnosed only when 
significant complications had ensued. The transmission mode is autosomal recessive and the 
disease manifests more commonly in males than in females, where natural iron losses are 
greater (Pietrangelo, 2004; Griffiths, 2007). In HH, gradual deposition of iron occurs in the 
liver and in a number of other tissues including the pancreas, joints, skin and heart. Disease 
manifestations include hepatic fibrosis, diabetes mellitus, arthropathy, pigmentation, 
cardiomyopathy and hypogonadotrophic hypogonadism. Fatigue and arthralgia are 
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common early symptoms and painful arthropathy is a considerable cause of morbidity. 
However, it is iron toxicity within the liver which increases mortality in patients with HH. 
Cirrhosis of the liver is associated with significantly reduced survival and there is a 200-fold 
increased risk of hepatocellular carcinoma (Pietrangelo, 2004; Griffiths, 2007; Swinkels et al., 
2006). 
 
 
Fig. 8. HFE -related Hereditary Hemochromatosis (adapted from Pietrangelo, 2004). 
The HFE gene encodes an HLA-A class 1-like protein and is located on 6p21.3, 4 megabases 
(Mb) telomeric to the human leukocyte antigen region (HLA). Two HFE mutations – C282Y 
(845 G>A) and H63D (187 C>G) – are significantly correlated with HH (Feder et al., 1996). 
The majority (60% to 90%) of clinically diagnosed probands are homozygous for C282Y, and 
5% are compound heterozygous for C282Y and H63D.  
The C282Y allele frequency in São Miguel population is 5.01%, a similar frequency (5.8%; de 
Fez et al., 2005; Gomes et al., 2007) to the obtained in the north of mainland Portugal, but 
statistically different from that observed in the south populations (0.9%; Cardoso et al., 
2001). Contrary to this C282Y decreasing gradient, the H63D presents an even country 
distribution (Figure 10), with values of 17.88% and 20.36% for mainland and São Miguel 
Island, respectively.  
Because C282Y mutation seems to have originated by chance on a HLA-A*03-B*07 
haplotype in an individual from northwestern Europe and early spread, by Celts or Vikings 
(Milman & Pedersen, 2003; Distante et al., 2004), in many countries including Portugal, the 
background of this mutation was assessed in São Miguel islanders (Gomes et al., 2007). Four 
www.intechopen.com
 The Genetic Makeup of Azoreans Versus Mainland Portugal Population 141 
non-ancestral HLA haplotypes were associated with C282Y: A*01-B*35, A*02-B*44, A*02-
B*55 and A*24-B*15, contrary to mainland, where the C282Y occurred mainly on the 
ancestral haplotype HLA-A*03-B*07 (Cruz et al., 2006). In addition, the C282Y mutation was 
also identified in two HLA A*03 bearing: A*03-B*27 and A*03-B*50. These results evidence 
that C282Y mutation was introduced in the Azorean population by individuals with genetic 
background other than Celts or Vikings.  
 
 
Fig. 9. Geographic distribution of HFE mutations in São Miguel Island. Frequency values are 
expressed in percentage. 
 
 
Fig. 10. Geographical distribution of the allelic frequencies of the C282Y and H63D HFE 
mutations in five Portuguese regions. (adapted from Cardoso et al., 2001). 
HFE – C282Y HFE – H63D 
www.intechopen.com
 Human Genetic Diseases 142 
4.3 Congenital heart disease 
The evaluation of genetic variants predisposing to complex diseases in Azores began with 
the characterization congenital heart diseases (CHD). Congenital malformations of the heart 
and great vessels are among the most frequent of all clinically significant birth defects, with 
a major contribution to paediatric morbidity, mortality and healthcare costs. 
  
 
Fig. 11. Three major classes of developmental defects are indicated: defects in atrial 
septation, in ventricular or atrioventricular septation, and in the great vessels. The types of 
congenital heart disease that occur within each class are indicated, with the associated 
mutated genes listed. AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal defect; 
AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; DORV, double outlet right 
ventricle; Ebstein’s, Ebstein’s anomaly of the tricuspid valve; HLHS, hypoplastic left heart 
syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, mitral atresia; 
MS, mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery stenosis; PTA, 
persistent truncus arteriosus; TA, tricuspid atresia; TAPVR, total anomalous pulmonary 
venous return; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; VSD, 
ventricular septal defect (From Bruneau, 2008). 
Population based epidemiologic studies indicate a prevalence of CHD ranging from 3.23 to 
12.23 per 1000 live births (Dolk et al., 2011; Bruneau, 2008; Engelfriet et al., 2005). This wide 
variation in the reported values is mainly due to the difference in the methodologies used, 
but a number of other factors, such as consanguinity, ethnic background, environmental 
pollutants and access to healthcare also contribute to this variation (Becker et al., 2001; 
Nabulsi et al. 2003; Botto et al., 2001). In 2006, the first study on the prevalence of CHD in 
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children born alive in São Miguel Island from January 1992 to December 2001 was carried 
out by Cymbron et al. (2006). Based on the Azorean Registry of CHD, which includes 
complete clinical and personal information, 189 patients were diagnosed. During this 10-
year period, the average prevalence of CHD is 9.16 per 1000 live births placing Azores in the 
10 European regions with higher prevalence of CHD (Table 5).  
 
Countries Total births N Prevalence (per 1000 births) 
Austria 62,667 960 15.32 
Malta 23,668 348 14.70 
Switzerland 42,874 576 13.43 
Germany 124,952 1457 11.66 
Poland 206,170 2304 11.18 
Norway 346,838 3538 10.20 
São Miguel Island 20,634 189 9.16 
Denmark 32,003 291 9.09 
France 343,715 2853 8.30 
Ukraine 25,835 201 7.78 
UK 951,001 6497 6.83 
Italy 431,727 2944 6.82 
Belgium 182,467 1212 6.64 
Ireland 215,021 1423 6.62 
Netherlands 119,104 732 6.15 
Spain 194,234 1080 5.56 
Croatia 33,933 182 5.36 
Total 3,356,843 26,787 7.97 
Table 5. Prevalence of CHG in European countries and São Miguel Island (adapted from 
Dolk et al., 2011). The period of time analysed was from 2000 to 2005, with the exception of 
São Miguel Island (1992 to 2001). No data for mainland Portugal is available. 
Considering that half of the São Miguel population lives in small rural localities (range from 
309 – 7407 inhabitants for Lomba de São Pedro and Rabo de Peixe, respectively) and the 
internal migration is reduced, aspects that increase endogamy and inbreeding, a structured 
family questionnaire to the parents with CHD children was performed. The questionnaire 
included i) questions for CHD risk factors – maternal diabetes mellitus, alcohol and drug 
abuse by the mother during pregnancy, viral infections of the fetus and genetic conditions –, 
ii) queries concerning the number of family members affected with CHD and parental 
consanguinity, and iii) a detailed family history to construct the ascending genealogy until 
the 3th generation. Results revealed a relatively high number of multiplex families (44; 
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40.37%, Table 6) and a significantly high value of consanguinity (9.17%). Half of the 
consanguineous families (5 out of 109 total families) are multiplex. In addition, 36 out of 44 
multiplex families are endogamous (81.8%; Table 7).  
The data suggest that genetic factors may be responsible for the development of CHD in São 
Miguel Island. Familial aggregation, which is of great interest for understanding the genes 
involved in these complex pathologies, is evident.  
 
Parameters 
Families (N=109) 
No. % 
Type of family:   
 Simplex 65 59.63 
 Multiplex 44 40.37 
Parental consanguinity:   
 With 10 9.17 
 Without 99 90.83 
Table 6. Parental consanguinity evaluation in CHD families from São Miguel Island. 
 
No. affected 
individuals 
per 
multiplex 
family 
No. 
families
Consanguinity
Distribution of families according to grandparental (GP) 
endogamy 
 
Same locality 
Different 
localities 
Do not 
know With Without Four GP Three GPTwo GP All GP 
2 26  3 23 5 5 10 3 3 
3 16 1 15 4 3 7 1 1 
4 1 0 1 - - 1 - - 
5 1 1 0 1 - - - - 
Total 44 5 39 10 8 18 4 4 
Table 7. Analysis of consanguinity and grandparental endogamy in multiplex families 
from São Miguel Island. 
Research has implicated both folate deficiency and genetic variation in folate pathway genes 
with birth defects, including CHD (Lee et al., 2005). Some studies suggest that 
polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene may be 
implicated in cardiac defects development. In mainland Portugal, Marinho et al. (2009) 
reported a higher prevalence of the 677T allele in tetralogy of Fallot (TF) compared to the 
control group (OR=1.675; 95% CI [1.022- 2.743]; p=0.05). The 677TT genotype increased by 
4.856 the risk for this congenital disease (95% CI [1.308-12.448]; p=0.028), suggesting that 
MTHFR can be considered a susceptibility gene for TF. Cabral et al. (2008) genotyped two 
polymorphisms, C677T and A1298C, in MTHFR in CHD children (N=95) and respective 
mothers (N=89), as well as in the control group (N=469; Table 8). No significant differences 
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were obtained between all studied groups, indicating that in São Miguel Island MTHFR 
C677T and A1298C polymorphisms are not the main cause of CHD development. Currently, 
further genetic studies, based on functional candidate genes, in the Azorean population are 
on-going. 
 
Variants  Allele frequency (%)  Genotype frequency (%) 
        
MTHFR - C677T  C T  CC  CT  TT  
Control group (N=469)  58.32 41.68  34.54 47.55 17.91 
CHD children (N=95)  57.89 42.11  29.47 56.84 13.68 
Mothers of CHD children 
(N=89) 
 62.92 37.08  39.33 47.19 13.48 
        
MTHFR - A1298C  A C  AA  AC  CC  
Control group (N=469)  75.16 24.84  56.29 37.74 5.97 
CHD children (N=95)  57.89 42.11  58.95 40.00 1.05 
Mothers of CHD children 
(N=89) 
 62.92 37.08  49.44 44.94 5.62 
Table 8. Allele and genotype frequencies for MTHFR C677T and A1298C polymorphisms 
in the São Miguel CHD study. 
4.4 Thrombosis 
In February 2007, the National Geographic Portugal magazine published a special issue 
dedicated to cardiovascular diseases. Based on the Euro Heart Survey 2006, the number of 
deaths per 100,000 inhabitants in 2004, due to CVD, places Portugal with higher values (390) 
compared with south-western European countries like Spain (290), France (262) and 
Belgium (364). In a similar analysis, performed within Portugal regions, the Azores 
archipelago clearly stands out with the highest value (116.9), followed by Lisbon (84.8). 
Family based investigation tends to have biased relative risk estimation, because 
oversampling of affected individuals is normally present. Therefore, the genetic 
characterization of disease variants in the general population is important to correct this 
potential bias. Since thrombosis is a common cause of CVD, Branco et al. (2009) analysed 
four polymorphisms in three thrombotic risk genes – F5 (G1691A), F2 (G20210A) and 
MTHFR (C677T, A1298C), in 469 healthy blood donors from São Miguel Island. Figure 12 
shows allele frequencies in Caucasian populations, including São Miguel, for the above 
mentioned polymorphisms.  
Comparison of allele frequencies for thrombotic risk factors between São Miguel and 
mainland Portugal (Mansilha et al., 2006) revealed statistically significant differences (2, 
p<0.001; Table 9) for F5 - 1691A, justifying the need to perform regional biomedical research 
to ultimately benefit the patient.  
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Fig. 12. Allele frequencies of the thrombotic risk factors – F5 (1691A), F2 (20210A) and 
MTHFR (677T, 1298C) – in different populations, including São Miguel (adapted from 
Branco et al., 2009). 
 
Allele frequency (%) 
Populations F5 (1691A) F2 (20210A) MTHFR (677T) MTHFR (1298C) 
São Miguel Island 4.9 1.8 41.7 24.8 
mainland Portugal 1.0 2.5 33.3 28.2 
Table 9. Comparison between thrombotic genetic risk variants frequency between Azoreans 
and mainland Portugal. 
Twenty-two different genetic profiles for F5, F2 and MTHFR (order in genotype profile) 
were observed in São Miguel's population (Figure 13). The frequency of individuals who 
present a wild-type genotype for all polymorphisms (GG GG CC AA; 11.7%) was almost 
half of the major profile (GG GG CT AA; 22.4%), differing in heterozygosity for MTHFR 
677CT. No heterozygous or homozygous profiles for all four variants were observed. 
Almawi et al. (2004) reported an OR of 10.5 (95% CI [4.3–25.3]) or 6.3 (95% CI [1.5–26.0]) for 
joint occurrence of the F5-G1691A or F2-G20210A with MTHFR-677TT genotype, 
respectively, enhancing the risk for deep vein thrombosis (DVT). Based on this criterion, 
fifteen (3.2%, F5/MTHFR) and two individuals (0.4%, F2/MTHFR) would have higher risk 
for DVT development (Figure 13 – asterisk character).  
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Fig. 13. Combined genotypes for thrombotic risk factors – F5, F2 and MTHFR – in São 
Miguel population. Twenty-two different genetic profiles were obtained. Bold characters 
(blue and black) indicate nucleotide changes compared to the wild-type allele. Blue bars 
represent profiles with increase genetic predisposition to thrombosis. The asterisk (*) 
represents the combination of the F5-G1691A or F2-G20210A with MTHFR-677TT genotype 
(adapted from Branco et al., 2009). 
Taken together, 12.4% (58 out of 469) of São Miguel islanders have increased genetic 
predisposition to thrombosis. No general population profile analysis for mainland Portugal 
is reported in the literature, and, consequently, no comparison was performed. These results 
are corroborated by further CVD studies, where 2 genomic regions associated with CVD 
risk, USF1 and 9p21 were evaluated (Correia et al., 2010). Preliminary results, based on 
haplotype inference, showed that USF1 “CCGCC” (0.288) and “CTGCT” (0.346) are the two 
most frequent haplotypes in Azoreans, which, according to Komulainen et al. (2006), 
correspond to the protective and high risk haplotype in females, respectively. In 9p21 
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region, the risk haplotype “TGGGCGCGC”, associated with CHD in Europeans (Silander et 
al., 2009), is the most frequent (0.414). Analysis of homozygosity patterns for risk genotypes 
showed similar frequencies for USF1 (12.4%) and 9p21 region (14.7%), indicating that, 
despite recombination, homozygosity must be taken in consideration when performing risk 
profile studies. Collectively, the data suggest that there is a considerable genetic risk for 
CVD in Azoreans, evidencing the need to carry out regional genetic studies with the aim to 
improve and complement health strategies adopted by the decision makers of each country. 
Further genetic studies on CVD are on-going. 
4.5 Pharmacogenetics of irinotecan and warfarin 
In the last 50 years, fundamental developments in pharmacology and genetics led to 
important improvements in personalized medicine based on pharmacogenetics and 
pharmacogenomics. Pharmacogenomics uses a whole genome approach to investigate or 
predict drug responses, or to relate the application of these technologies to drug discovery, 
while pharmacogenetics is the study of the clinically relevant inherited differences in drug 
response that can be in part explained by genetic variations. Pharmacogenetic analysis 
contributes to reduce adverse drug reactions (ADRs) or to maximize drug efficiency. 
Variants involved in drug metabolism of two commonly prescribed drugs, irinotecan and 
warfarin, were studied in Azoreans and mainland Portugal.  
4.5.1 Pharmacogenetics of irinotecan  
Irinotecan, an antineoplastic-prodrug, is widely used for the treatment of colorectal, lung 
and other cancers. The most clinically significant adverse events for patients receiving 
irinotecan-based therapy are diarrhea, neutropenia, nausea, vomiting and alopecia (Kehrer 
et al., 2001; Marques & Ikediobi, 2010; Lankisch et al., 2008; Fujiwara & Minami, 2010). 
Irinotecan can induce both early and late forms of diarrhea and requires dose adjustment 
based on severity of diarrhea. Also, sepsis related death following severe neutropenia has 
been reported in irinotecan treated patients. The active metabolite SN-38 is responsible for 
the pharmacological and toxic effect of irinotecan. SN-38, is a topoisomerase I inhibitor 
generated by hydrolysis of irinotecan by carboxylesterases (Figure 14). SN-38 is 
subsequently glucuronidated by uridine diphosphate glucuronosyltransferase 1As 
(UGT1As) to form an inactive metabolite, SN-38G (Marques & Ikediobi, 2010; Fujiwara & 
Minami, 2010).  
The human UDP-glucuronosyltransferase 1A gene locus is organized to generate enzymes, 
which share a carboxyterminal portion and are unique at their aminoterminal variable 
region. Expression is tissue-specific and overlapping substrate specificities include a broad 
spectrum of endogenous and xenobiotic compounds, as well as many therapeutic drugs 
targeted for detoxification and elimination by glucuronidation. The absence of 
glucuronidation leads to fatal hyperbilirubinemia (Marsh & Hoskins, 2010; Zhang et al., 
2007). Genetic variants and haplotypes have been identified as risk factors for unwanted 
drug effects of cancer treatment with irinotecan. Since variants in UGT1A1, UGT1A6 and 
UGT1A7 are related to irinotecan toxicity, these were studied in 469 individuals from São 
Miguel Island by Pacheco et al. (2009). Haplotype analysis revealed that H3 (Table 10), 
which includes all low activity allelic variants of the three UGT isoforms, accounts for 23.5% 
of the population, suggesting that those individuals have reduced glucuronidation activity 
due to the combination of UGT1A1*28, UGT1A6*2 and UGT1A7*3 alleles.  
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Fig. 14. Irinotecan pathway indicating tissue specific involvement of genes in the irinotecan 
metabolism. PharmGKB copyright. Available at 
http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp. 
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  UGT1A genes  
Haplotype 
frequency Haplotype 
(H) 
UGT1A1 UGT1A6 UGT1A7 
A[TA]nTAA 541 552 541/552 387 391/392 622 387/391/392/622 N (2N=938) 
01 TA6 (*1) A A *1 T C-G T *1 296 0.316 
02 TA6 (*1) A A *1 G A-A T *2 225 0.240 
03 TA7 (*28) G C *2 G A-A C *3 220 0.235 
04 TA6 (*1) A A *1 G A-A C *3  65 0.069 
05 TA6 (*1) G C *2 G A-A C *3  31 0.033 
06 TA6 (*1) A C *3 G A-A T *2  26 0.028 
07 TA7 (*28) A A *1 T C-G T *1  23 0.024 
08 TA6 (*1) A A *1 T C-G C *4  17 0.018 
09 TA7 (*28) G C *2 G A-A T *2  7 0.007 
10 TA7 (*28) A C *3 G A-A T *2  6 0.006 
11 TA7 (*28) A A *1 G A-A T *2  5 0.005 
12 TA7 (*28) A A *1 G A-A C *3  5 0.005 
13 TA7 (*28) A C *3 G A-A C *3  3 0.003 
14 TA7 (*28) A C *3 T C-G C *4  3 0.003 
15 TA5 (*36) A A *1 G A-A T *2  2 0.002 
16 TA6 (*1) A C *3 T C-G C *4  2 0.002 
17 TA7 (*28) A A *1 T C-G C *4  2 0.002 
18 TA6 (*1) A C *3 T C-G T *1  1 0.001 
19 TA8 (*37) G C *2 G A-A C *3  1 0.001 
Table 10. Haplotype frequencies of UGT1A1, UGT1A6 and UGT1A7 variants in São Miguel 
Island population. UGT1A6 alleles are defined by permutations of two SNPs (nucleotide 
positions 541A>G and 552A>C) and UGT1A7 by permutations of four SNPs (387T>G, 
391C>A and 392G>A, and 622T>C; adapted from Pacheco et al., 2009). 
4.5.2 Pharmacogenetics of warfarin  
Warfarin is one of the most widely used anticoagulant drug, which requires a thorough risk-
benefit analysis since the dose prescribed should avoid hemorrhagic complications and 
achieves suppression of thrombosis (Wadelius & Pirmohamed, 2007; You 2011; Limdi & 
Veenstra, 2008). The administrated drug is a racemic mixture of S- and R-enantiomers, 
having S- the majority of the therapeutic effect (Figure 15). Warfarin pharmacogenetic 
studies demonstrated that variants in the CYP2C9 (Cytochrome P450 2C9) and VKORC1 
(Vitamin K epoxide reductase complex subunit 1) genes account for approximately 50–60% 
of drug dosing variability (Finkelman et al., 2011). The remaining variability can be 
explained by clinical and environmental factors (age, sex, diet, concomitant drugs, body 
mass index), which in conjunction with genetics are used, in warfarin dosing algorithms, as 
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an advice for the best dose prescription. Cytochrome P450 2C9 is the major enzyme 
responsible for metabolising the active S-enantiomer. Although there are many 
polymorphisms in CYP2C9, the most clinically relevant variants are: CYP2C9*1 
(Arg144/Ile359, wild-type), CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu). These last 
two are associated with decreased metabolic efficiency of the CYP2C9 enzyme and 
increased risk of bleeding when administrated initial dosages of warfarin (Yasar et al., 1999). 
Considering VKCORC1, a G>A variation at position 1639 in the gene’s promoter region 
results in decreased mRNA transcription and increased sensitivity to warfarin inhibition of 
hepatic synthesis of functional vitamin K-dependent coagulation factors. Rieder et al. (2005) 
studied VKORC1 polymorphisms and classified individuals according to warfarin dose 
requirements into distinct groups: high (GG), intermediate (GA) and low (AA). Recently, the 
U.S. Food and Drug Administration (FDA) added to the warfarin product label dosing 
recommendations stratified by combined CYP2C9 and VKORC1 genotypes 
(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm08337
8.htm).  
 
 
 
 
Fig. 15. Warfarin pharmacokinetic and pharmacodynamic pathway. Warfarin is 
administered as a racemic admixture of R- and S-enantiomers. The more potent S-
enantiomer is metabolized principally by CYP2C9. The pharmacological effect of warfarin is 
mediated by the inhibition of vitamin K epoxide reductase complex 1 (VKORC1). This 
results in decreased concentrations of activated clotting factors (II, VII, IX and X) producing 
therapeutic anticoagulation (adapted from Božina 2010). 
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Comparison of separate genotypes for CYP2C9 and VKORC1 between mainland Portugal 
(Jorge et al., 2010) and the Azores (Pereirinha et al., 2009, personal communication) 
populations revealed no significant differences (Table 11). In the Azores population no 
individuals with CYP2C9-*3*3 genotype were identified, however a higher frequency of 
CYP2C9-*2*3 was observed when compared to mainland. The joint analysis of CYP2C9 and 
VKORC1, in Azoreans, showed that around 12% of individuals need low doses of warfarin, 
if treatment is started (Table 11; blue characters).  
 
CYP2C9 VKORC1 CYP2C9 /VKORC1 
Genotype Frequency (%) Genotype Frequency (%) Genotype Frequency (%) 
 Azores m. 
Portugal  
 Azores  m. 
Portugal  
 Azores  m. 
Portugal  
*1/*1 57.6 64.0 GG 30.0 33.0 *1*1-GG 17.1 NA 
*1/*2 25.3 22.0 GA 56.5 50.5 *1*1-GA 34.1 NA 
*1/*3 8.2 9.0 AA 13.5 16.5 *1*2-GG 7.0 NA 
*2/*2 5.3 3.3    *1*3-GG 2.4 NA 
*2/*3 3.5 1.1    *1*1-AA 6.4 NA 
*3/*3 0 1.1    *1*2-GA 13.5 NA 
      *1*3-GA 4.1 NA 
      *2*2-GG 1.8 NA 
      *2*3-GG 1.8 NA 
      *1*2-AA 4.7 NA 
      *1*3-AA 1.8 NA 
      *2*2-AA 0.6 NA 
      *2*2-GA 2.9 NA 
      *2*3-GA 1.8 NA 
Table 11. Genotype frequencies of CYP2C9 and VKORC1 variants in Azores (N=170) and 
mainland Portugal (N=91) populations. NA- not applicable; no joint analysis of both genes 
has been described for mainland Portugal populations. Blue characters represent 
individuals who would require low doses of warfarin.  
Overall, irinotecan and warfarin studies demonstrated that the Azores population shows 
significant differences on allele frequencies of pharmacogenetic variants, which must be 
taken in consideration when treating patients. These results have a high impact on the 
physicians’ decisions in managing patient’s treatment.  
5. Conclusion 
Genomic medicine, which uses the individual information to provide better healthcare, has 
been considerably developed since the Human Genome Project. One of its current 
challenges is the identification of risk alleles for multifactorial diseases and the study of their 
frequency in different populations. In summary, both the Azores and mainland Portugal 
populations are outbred with high genetic diversity, relative gene flow among its 
individuals, and without extensive LD. Nevertheless, the islanders have a particular genetic 
makeup evidenced by the African and Asian traits, and by the differences in terms of 
common diseases apportionment compared to mainland. Biomedical investigation has been 
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the driving force in improving practices in patient care, based on new drugs, diagnostic 
methods, medical instruments and services. The genetic research performed in the Azorean 
population allowed the implementation of molecular diagnosis in the main Hospital of the 
archipelago, as well as a faster and most costly effective response to clinicians, benefiting the 
patient and, ultimately, the Azorean Health System. 
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